Lv4
480 积分 2021-10-19 加入
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
11小时前
待确认
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials
11小时前
已完结
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
11小时前
已完结
A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection
14小时前
已完结
Safety and antiviral activity of RBD1016, a RNAi therapeutic, in Chinese subjects with chronic hepatitis B virus (HBV) infection
16小时前
已完结
Metabolite Identification and Quantitation of RBD1016 siRNA: A Direct Comparison of Hybridization-Based LC-FD and LC-HRAM Assays
16小时前
已完结
Pharmacokinetic insights of onradivir in influenza treatment to inform pediatric dosing selection in clinical trial
1个月前
已完结
A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3
10个月前
已完结
Natural Product-Inspired Discovery of Naphthoquinone-Furo-Piperidine Derivatives as Novel STAT3 Inhibitors for the Treatment of Triple-Negative Breast Cancer
10个月前
已完结
Probing the Depths of Molecular Complexity: STAT3 as a Key Architect in Colorectal Cancer Pathogenesis
10个月前
已完结
皖公网安备34019202002308
